To determine whether resistance to BGJ398 resulted in cross-resistance to other FGFR inhibitors, including erdafitinib which was recently approved for FGFR2/3 driven bladder cancers, and the covalently binding irreversible FGFR inhibitor TAS-120 (futibatinib) [31] which is currently in early-phase clinical trials, sensitive and resistant clones were treated with increasing doses of both agents and growth inhibition assessed by CTG assay. Here, FGFR2 is linked to urinary bladder carcinoma.